| Drug General Information |
| Drug ID |
D0IJ7O
|
| Former ID |
DNC000928
|
| Drug Name |
Metastat
|
| Drug Type |
Small molecular drug
|
| Indication |
Acne vulgaris [ICD9: 706.1; ICD10:L70.0]
|
Phase 1 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H17NO7
|
| CAS Number |
CAS 15866-90-7
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
72 kDa type IV collagenase |
Target Info |
Inhibitor |
[3]
|
|---|
|
KEGG Pathway
|
Leukocyte transendothelial migration
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Bladder cancer
|
|
NetPath Pathway
|
Leptin Signaling Pathway
|
|
TCR Signaling Pathway
|
|
ID Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Direct p53 effectors
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
Syndecan-2-mediated signaling events
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
EPH-ephrin mediated repulsion of cells
|
|
WikiPathways
|
Activation of Matrix Metalloproteinases
|
|
AGE/RAGE pathway
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00001683) A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. U.S. National Institutes of Health. |
|---|
| REF 2 | A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res. 2004 Oct 1;10(19):6512-21. |
|---|
| REF 3 | Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72. |
|---|
